Dapagliflozin 10 mg & Metformin HCl 1000 mg ER Tablets — Tablets
WHO-GMP Certified Commercial Pack · Product Code: AKP-100-DM

Dapagliflozin 10 mg & Metformin HCl 1000 mg ER Tablets

Formulation Overview: Once-daily insulin-independent SGLT2 inhibitor dapagliflozin 10 mg combined with extended-release metformin HCl (1000 mg) promoting urinary glucose excretion alongside hepatic gluconeogenesis suppression. Formulated with Dapagliflozin 10 mg + Metformin HCl 1000 mg (ER) (10 mg + 1000 mg (ER)) in Extended-Release Bilayer Tablets dosage form under Anti-Diabetic Medication, manufactured to IP / BP / USP Compendial standards and supplied in 10 x 10 Alu-Alu / Blister Pack with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
Item Code (SKU)AKP-100-DM
Catalog ReferenceAKP-100 · SN 100
Therapeutic SectorAnti-Diabetic Medication
Dosage FormExtended-Release Bilayer Tablets
Active IngredientDapagliflozin 10 mg + Metformin HCl 1000 mg (ER)
Strength / Purity10 mg + 1000 mg (ER)
Clinical IndicationType 2 diabetes mellitus glycemic control, cardiovascular-renal risk reduction, and weight-favorable glucose lowering
Specification StandardIP / BP / USP Compendial
Packaging Format10 x 10 Alu-Alu / Blister Pack
Shelf Life24–36 Months
Storage ConditionsStore below 25°C in a dry place, protect from light and moisture
Minimum Order Quantity1000 Packs
Regulatory / Analytical DocsFull eCTD / ACTD Modules 1–5 + Zone IVb Stability Available
African & Global NRA ReadinessNAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA
Stock AvailabilityIn Stock · Immediate Commercial Dispatch
Supply StatusCommercial Export Ready

Related Tablets & Anti-Diabetic Medication